Evidence map›Paper›PMID 16096831›Full record

Trial reportWorld journal of urology2005

Efficacy and tolerability of darifenacin, a muscarinic M3 selective receptor antagonist (M3 SRA), compared with oxybutynin in the treatment of patients with overactive bladder.

Norman Zinner, John Tuttle, Leonard Marks

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in World journal of urology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02385500 (Randomized Cross-Over Study of Fesoterodine on Urgency Episodes in Parkinson's Disease Population), which is not on this map. Cited by 30 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 8 pooled it
7.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02385500 phase4terminatednot on this mapstarted 2016, after this paper: background citation

Randomized Cross-Over Study of Fesoterodine on Urgency Episodes in Parkinson's Disease Population

TypeinterventionalSponsorSir Mortimer B. Davis - Jewish General HospitalRan2016 to 2019Enrolled5ConditionsUrinary Bladder, Overactive, Parkinson DiseaseArmsFesoterodine, Placebo
3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 8 syntheses or guidelines pooled it, 97 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. The Effectiveness of Anticholinergic Therapy for Overactive Bladders: Systematic Review and Meta-Analysis.Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia · 2016
    Pooled it
  4. Which anticholinergic drug for overactive bladder symptoms in adults.The Cochrane database of systematic reviews · 2012
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Overactive bladder - 18 years - Part II.International braz j urol : official journal of the Brazilian Society of Urology
    Pooled it
  9. Trial
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. A multivariate approach linking reported side effects of clinical antidepressant and antipsychotic trials to in vitro binding affinities.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2014
    Article
  17. Article
  18. Management of urinary incontinence.P & T : a peer-reviewed journal for formulary management · 2012
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 1 country.

Norman ZinnerWestern Clinical Research, Inc., Los Angeles, California, USA. wewedoc@aol.com
John Tuttle
Leonard Marks
Kentucky Educational Television · USUniversity of California, Los Angeles · USWest Coast University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A randomized, double-blind, placebo-controlled, four-way crossover, safety study of darifenacin versus oxybutynin was carried out on 76 patients with overactive bladder (OAB). Adults with OAB received 2 weeks each of darifenacin 15 and 30 mg once daily (q.d.), oxybutynin 5 mg three times daily (t.i.d.) and placebo, in random sequence at 10-day intervals. Darifenacin and oxybutynin significantly reduced incontinence episodes, and the number/severity of urgency episodes (all P<0.05 versus placebo). Improvements in OAB symptoms with darifenacin were dose-dependent. Dry mouth was less common with darifenacin 15 mg than oxybutynin (13% and 36%; P<0.05), while constipation was comparable (10% and 8%, respectively). Corresponding rates for darifenacin 30 mg were 34% and 21%, respectively. Patients only reported blurred vision or dizziness with oxybutynin (3% and 2%, respectively). Darifenacin (15 mg q.d.) provides comparable efficacy with improved tolerability versus oxybutynin (5 mg t.i.d.) in the treatment of patients with OAB.

Indexed as

AdolescentAdultAgedAged, 80 and overBenzofuransCross-Over StudiesDouble-Blind MethodFemaleHumansMaleMandelic AcidsMiddle AgedPyrrolidinesReceptor, Muscarinic M3Treatment OutcomeUrinary IncontinenceBenzofuransdarifenacinMandelic AcidsoxybutyninPyrrolidinesReceptor, Muscarinic M3

Identifiers

PMID16096831
OpenAlexW2067924801

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.